天大藥業(00455.HK)擴大珠海基地產能 滿足防疫藥品需求
天大藥業(00455.HK)公布,位於珠海基地的生產線正在全力生產布洛芬等市場必需藥品,以保障市場供應。為確保公司藥品供應暢順,集團決定提速擴大珠海基地產能,新建液體車間生產線,力爭在最短時間內完成,以滿足旗下產品包括布洛芬混懸液、美敏偽麻、液體製劑CDMO項目的生產,並將小兒清熱止咳顆粒的生產外包,擴大產量。
同時,集團進一步將旗下中醫館連鎖「天大館」的中醫藥系列服務投入支援內地疫情家居防控,向民眾提供網上免費中醫診證服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.